Drug Profile

Trabikibart - CSL

Alternative Names: CSL-311; CSL311-anti-Beta Common

Latest Information Update: 12 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CSL
Class Antiasthmatics; Monoclonal antibodies
Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Interleukin 3 receptor antagonists; Interleukin 5 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Nov 2023 CSL Behring completes a phase I trial in Asthma in Germany and United Kingdom (IV) (NCT04082754) (EudraCT2019-001135-32)
18 Oct 2023 CSL 311 is still in phase I trials for Asthma in United Kingdom (IV) (CSL pipeline, October 2023)
28 Dec 2022 No recent reports of development identified for phase-I development in Asthma in United Kingdom (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com